Pfizer lung-cancer drug fails in two Phase III studies


Pfizer's (PFE -0.3%) Dacomitinib drug has failed in two Phase III trials of patients with refractory advanced non-small cell lung cancer.

In the ARCHER 1009 trial, which included patients previously treated with chemotherapy, Dacomitinib did not significantly improve progression-free survival (PFS) when compared with the Erlotinib (Tarceva) drug.

In the second study, Dacomitinib was unable to lengthen survival vs a placebo.

A third Phase III trial is assessing Dacomitinib in a different patient population, with the results expected in 2015. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs